* L’évolution de la myopie cliniquement significative est définie comme une variation de l’équivalent sphérique inférieure ou égale à -0,50 D sur 12 mois de port. Résultats observés chez des enfants myopes âgés de 4 à 12 ans. Les résultats peuvent varier selon l’âge et d’autres paramètres au début du traitement par MiYOSMART iQ.
1. Tricard D, Marillet S, Ingrand P, Bullimore MA, Bourne RRA, Leveziel N. Progression of myopia in children and teenagers: a nationwide longitudinal study. Br J Ophthalmol. 2022 Aug;106(8):1104-1109. doi: 10.1136/bjophthalmol-2020-318256. Epub 2021 Mar 12. PMID: 33712479; PMCID: PMC9340031
2. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136.
3. Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D. K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA.
https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941 (accessed date 03.04.2026)
4. HOYA data on file. HOYA MiYOSMART iQ spectacle lens clinical outcomes. 04/2026.
5. Lam CSY, Tang WC, Zhang HY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023;13(1):5475. DOI: 10.1038/s41598-023-32700-7.
6. Leung et al. Comparison of Myopia Progression in Individuals Wearing DIMS Spectacle Lenses for Eight Years versus Shorter Durations. Abstract presented at ARVO 2025.
Available at: https://www.hoyavision.com/globalassets/__regional-assets/global/arvo-2025/leung-et-al.-dims-8y-study-arvo-2025-abstract.pdf.